LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Arrowhead Pharmaceuticals Inc

Fechado

SetorSaúde

16.78 2.13

Visão Geral

Variação de preço das ações

24h

Atual

Mín

16.45

Máximo

17.09

Indicadores-chave

By Trading Economics

Rendimento

546M

370M

Vendas

540M

543M

EPS

2.75

Margem de lucro

68.258

Funcionários

609

EBITDA

554M

405M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+138.94% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

167M

2.3B

Abertura anterior

14.65

Fecho anterior

16.78

Sentimento de Notícias

By Acuity

79%

21%

359 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Arrowhead Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de set. de 2024, 10:38 UTC

Grandes Movimentos do Mercado

Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran

Comparação entre Pares

Variação de preço

Arrowhead Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

138.94% parte superior

Previsão para 12 meses

Média 39.33 USD  138.94%

Máximo 80 USD

Mínimo 17 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Arrowhead Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

12 ratings

7

Comprar

5

Manter

0

Vender

Pontuação Técnica

By Trading Central

11.5 / 12.23Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

359 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.